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Fungi are an attractive source of physiologically functional foods and drug precur-
sors, displaying a wide range of pharmacological activities such as anticancer, anti-in-
flammatory, antitumor and immunomodulating effects (1). Antitumor polysaccharides
such as krestin, lentinan and schizophyllan have been isolated from various fungi. Poly-
saccharides from natural sources have diverse immunomodulatory activities both in vi-
tro and in vivo. They are known modulators of cellular and humoral immunity. Polysac-
charides derived from fungi are known for their antitumor and immunomodulating pro-
perties. They exert antitumor activity through activation of various immune responses
in the host. Further, different strains of Basidiomycetes produce polysaccharides of vary-
ing properties (2, 3).
Ganoderma lucidum, a fungus grown on rotten wood, is a well known source of ther-
apeutic agents. G. lucidum, commonly known as 'Reishi' or 'Lingzhi', has been extensi-
vely used in oriental folk medicine for thousands of years to treat various diseases, in-
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In this study, polysaccharides were isolated from Gano-
derma lucidum (Polyporaceae) and their antitumor and anti-
-inflammatory activities were investigated using in vivo
models. Potential antitumor activity was shown by G. lu-
cidum polysaccharides (GLP) against solid tumor induced
by Ehrlich’s ascites carcinoma cells. GLP at 100 mg kg–1
body mass showed 80.8 and 77.6 % reduction in tumour
volume and tumour mass, respectively, when administe-
red 24 h after tumour implantation. Again, GLP at the sa-
me dose but when administered prior to tumour inocu-
lation, showed 79.5 and 81.2 % inhibition of tumour vol-
ume and tumour mass, respectively. GLP showed signifi-
cant dose-dependent activity in carrageenean-induced
(acute) and formalin-induced (chronic) inflammation as-
says. At 100 mg kg–1, GLP exhibited 57.6 and 58.2 % in-
hibition in carrageenean-induced and formalin-induced
assays, respectively.
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cluding cancer (4). Further, it has been reported to have antioxidant, anti-inflammatory,
antitumor, antihypertensive, antihistaminic and antihepatotoxic effects. Cytotoxic triter-
penoids and immunomodulating polysaccharides are the major chemical constituents of
G. lucidum (5). In vitro studies showed that the administration of polysaccharides iso-
lated from G. lucidum spores could effectively inhibit growth in mice with transplanted
S180 sarcoma (6). Here, we report the in vivo anti-inflammatory and antitumour activi-
ties of the polysaccharide isolates (GLP) of G. lucidum from southern India.
EXPERIMENTAL
Plant material
G. lucidum (Polyporaceae) fruiting bodies were collected from Thrissur district in Ke-
rala, India. A voucher specimen was deposited at the Herbarium of the Centre for Ad-
vanced Studies in Botany, University of Madras, Chennai, India.
Isolation of G. lucidum polysaccharides
Fruiting bodies of G. lucidum (200 g) were cut into small pieces, dried at 40–50 °C for
48 h and powdered. Powdered mushroom was defatted with petroleum ether. Defatted
G. lucidum powder was extracted with doubly distilled water (1:25, m/V) at 80 °C for 8 h.
This extract was filtered and concentrated at 40 °C in a rotary vacuum evaporator (Büchi
Rotavapor R-114, Switzerland). Ethanol (95 %) was added to the concentrated aqueous
extract (5:1, V/V), stirred vigorously and kept at 4 °C for 48 h. The polysaccharides
which precipitated out were collected by centrifugation at 16,800 ´ g for 20 min. The pre-
cipitate obtained was washed with ethanol and dried. The residue thus obtained was
dissolved in deionised water, loaded on a DEAE cellulose column and eluted with de-
ionised water. The fractions obtained were treated with diluted HCl followed by anthro-
ne reagent. Green colour indicated the presence of polysaccharides. All anthrone posi-
tive fractions were combined and re-peatedly shaken with Sevag’s reagent to remove the
proteins (7). After protein removal, the polysaccharides were again re-precipitated with
chilled ethanol (95 %), and this precipitate was dissolved in deionised water and dia-
lyzed (1:1.00,000) in water for 48 h. On testing with phenol/H2SO4 reagent, this fraction
showed a violet colour indicating polysaccharides. It was then evaporated at low tempe-
rature and lyophilized to obtain G. lucidum polysaccharide fraction (GLP, 900 mg, 0.4 %)
as a light brown powder.
Animals
Male Swiss albino mice were procured from the Small Animal Breeding Centre, Vet-
erinary College, Thrissur, India. Animals were kept for a week under environmentally
controlled conditions before experimentation. They were fed a standard diet and water
ad libitum. Mice weighing 25 ± 2 g were used. All animal experiments were carried out
with the approval and according to the guidelines of the Institutional Animal Ethics
Committee.
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Cell line
Ehrlich’s ascites carcinoma (EAC) cell line was obtained from Adyar Cancer Insti-
tute, Chennai, India. The cells were maintained by intraperitoneal inoculation of 1 × 106
viable cells in mice.
Determination of antitumor activity
Antitumor activity of GLP was determined using two solid tumor models.
Antitumor activity of GLP when administered after tumor cell implantation. – Animals
were divided into five groups of six animals each (8). Viable EAC cells 1 ´ 106 in 0.1 mL
PBS were transplanted subcutaneously into the right groin of mice. GLP (25, 50 and
100 mg kg–1 body mass) was administered 24 h after tumor cell implantation and contin-
ued for ten consecutive days. The control group received normal saline instead of GLP.
Cyclophosphamide (25 mg kg–1) was used as the reference standard drug. GLP and
standard drug were administered using a 22-guage oral cannula for mice. Tumor devel-
opment in animals of each group was determined by measuring the diameter of tumor
growth in two perpendicular planes using vernier calipers twice a week for five weeks.
Tumor volume was calculated using the formula 4/3pr12r2, where r1 is the minor diame-
ter and r2 is the major diameter. At the end of the fifth week, animals were sacrificed un-
der anesthesia using diethyl ether. The tumors were extirpated, weighed and the percent
inhibition was calculated (9).
Antitumor activity of GLP when administered prior to tumor cell implantation. – GLP (25,
50 and 100 mg kg–1 body mass) was administered for ten consecutive days followed by
tumor cell implantation which was carried out 1 h after the last dose of GLP administra-
tion cells (8). Animals were kept untreated after tumor implantation. Control group re-
ceived only normal saline. Cyclophosphamide (25 mg kg–1) was used as the reference
drug. Initiation of tumor growth was observed. Tumor diameter was measured using
vernier calipers twice a week for a period of three weeks. At the end of the third week,
the animals were sacrificed, tumors were extirpated, weighed and percentage inhibition
was calculated (9).
Determination of anti-inflammatory activity
Carrageenean-induced edema. – Animals were divided into four groups of six animals
each. Acute inflammation was produced in all animals by subplantar injection of 20 mL
freshly prepared 1 % suspension of carrageenean in normal saline to the right hind paw
of mice (10). Paw thickness was measured using vernier calipers before and after carra-
geenean injection in each group. Animals were premedicated with GLP (25, 50 and 100
mg kg–1 body mass), and with the reference drug diclofenac (10 mg kg–1), orally 1 h be-
fore carrageenean injection.
Formalin-induced edema. – Animals were treated exactly as in the carrageenean-in-
duced method but instead of carrageenean, freshly prepared 2 % formalin in normal sa-
line (20 mL) was used as the edematogenic agent. Drug treatment was continued for six
consecutive days (11). In both carrageenean-induced and formalin-induced models, the
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degree of edema formation was determined as the increase in paw thickness. The per-
cent inhibition was calculated as reported by Ajith and Janardhanan (12).
Statistical analysis
The data were statistically analyzed using Student’s t-test. All data were represen-
ted as mean ± SD.
RESULTS AND DISCUSSION
Polysaccharides isolated from fruiting bodies of G. lucidum (GLP) showed signifi-
cant antitumour activity against solid tumor. GLP, when administered 24 h after tumor
implantation at doses of 25, 50 and 100 mg kg–1 body mass, inhibited 64.3, 73.4 and 80.8 %
of tumor volume and 58.3, 67.6 and 77.6 % of tumor mass, respectively, comparable to 71.8
and 73.8 % achieved by 25 mg kg–1 cyclophosphamide, resp. (Table I). The tumor vol-
ume and mass in GLP treated groups of animals were significantly lower than in the
control group. At 100 mg kg–1, GLP inhibited tumor proliferation as effectively as the
standard reference drug cyclophosphamide at 25 mg kg–1. Pretreatment with GLP was
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Table I. Antitumor activity of GLP against solid tumor induced by Ehrlich's ascites carcinoma cells
Treatment Initial tumor volume (cm3)a Initial tumor mass (g)a
Antitumor activity of GLP when administered after tumor implantation
Controlb 0.2790 ± 0.0191 4.19 ± 0.55
Cyclophosphamide
(25 mg kg–1)
0.0786 ± 0.0173c 1.10 ± 0.21e
Polysaccharide
25 mg kg–1 0.0996 ± 0.0230d 1.75 ± 0.27
50 mg kg–1 0.0741 ± 0.0134c 1.36 ± 0.28
100 mg kg–1 0.0535 ± 0.0029e 0.93 ± 0.07e
Antitumor activity of GLP when administered prior to tumor implantation
Controlb 0.2037 ± 0.0280 4.74 ± 0.29
Cyclophosphamide
(25 mg kg–1)
0.3600 ± 0.0080e 0.98 ± 0.02e
Polysaccharide
25 mg kg–1 0.0891 ± 0.0084e 2.0 ± 0.24e
50 mg kg–1 0.0640 ± 0.0085e 1.6 ± 0.30e
100 mg kg–1 0.0416 ± 0.0113e 0.89 ± 0.02e
a Mean ± SD (n = 6).
b Normal saline, 0.8 mL per animal.
Significant difference with respect to control: c p < 0.01, d p < 0.005, e p < 0.001.
also effective in inhibiting tumor proliferation induced by EAC cells. Administration of
the same doses of GLP for ten consecutive days prior to tumor inoculation inhibited
56.3, 68.4 and 79.5 % of tumor volume and 56.8, 65.2 and 81.2 % of tumor mass, respec-
tively, whereas the standard drug cyclophosphamide (25 mg kg–1 body mass) inhibited
82.3 % tumor volume and 79.2 % tumor mass (Table I).
At 25, 50 and 100 mg kg–1 body mass, GLP inhibited acute inflammation induced by
carrageenean and chronic inflammation induced by formalin in a dose dependent man-
ner (Figs. 1a,b). At 100 mg kg–1 body mass GLP showed activity comparable to that of
diclofenac (10 mg kg–1) in both assays. Thus, the present study has confirmed strong
anti-inflammatory activity of the polysaccharides isolated from the southern Indian ac-
cession of G. lucidum.
The main components of G. lucidum polysaccharides are b-1,3 and b-1,6-D-glucans
(Fig. 2). b-D-glucan is a carbohydrate polymer with chains of glucose molecules linked
together by b-glycosidic linkages (13). G. lucidum is traditionally used for the prevention
and treatment of a large number of diseases, including many forms of cancer. G. lucidum
extracts and polysaccharides were also proven to have, along with antitumor, also im-
mune potentiating activities (14, 15). G. lucidum polysaccharides were shown to induce
apoptosis, inhibit cell proliferation and suppress cell migration of highly invasive hu-
man prostate cancer cells. The mechanism of antitumor activity of G. lucidum polysac-
charides proceeded through stimulation of host defence responses (14, 15). Our earlier
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Fig. 1. Effect of GLP on: a) carrageenean-induced acute inflammation, b) formalin-induced chronic
inflammation; G. lucidum polysaccharide fractions 1: 25; 2: 50; 3: 75 mg kg–1; 4: diclofenac (10 mg
kg–1). SD bars, n = 6. Significant difference with respect to control: * p < 0.01.
studies reported antitumor, antioxidant (16), anti-inflammatory and antinociceptive ac-
tivities (17) exhibited by crude extracts of southern Indian accessions of G. lucidum.
CONCLUSIONS
The present study has shown that an isolated polysaccharide fraction of G. lucidum
has marked antitumor and anti-inflammatory activities. These results on polysacchari-
des and previous data on extracts suggest the therapeutic potential of southern Indian
strains of G. lucidum.
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S A @ E T A K
Citostatsko i protuupalno djelovanje polisaharida biljke Ganoderma lucidum
SONIAMOL JOSEPH, BABY SABULAL, VARUGHESE GEORGE, KUTTIKKADAN RONY
ANTONY i KAINOOR KRISHNANKUTTY JANARDHANAN
U radu je ispitano in vivo citostatsko i protuupalno djelovanje polisaharida (GLP)
izoliranih iz biljke Ganoderma lucidum (Polyporaceae). Ispitivani polisaharidi pokazali su
potencijalno antitumorsko djelovanje na Ehrlichov ascitesni tumor. GLP su u dozi od
100 mg kg–1 tjelesne mase inhibirali volumen tumora za 80,8, a njegovu masu za 77,6 %,
kada su primijenjeni 24 h nakon implantacije tumora. Ako se GLP daju u istoj dozi prije
inokulacije tumora, inhibiraju volumen tumora za 79,5, a njegovu masu za 81,2 %. GLP
pokazuju zna~ajno, o dozi ovisno, protuupalno djelovanje u karagenan testu (akutna
341
S. Joseph et al.: Antitumor and anti-inflammatory activities of polysaccharides isolated from Ganoderma lucidum, Acta Pharm. 61
(2011) 335–342.
upala) i formalin testu (kroni~na upala). U dozi od 100 mg kg–1, GLP inhibiraju upalne
procese za 57,6 odnosno 58,2 % u testu s karagenanom, odnosno formalinom.
Klju~ne rije~i: Ganoderma lucidum (Polyporaceae), polisaharidi, protuupalno djelovanje, citostatsko
djelovanje
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